HIV VACCINE DESIGN AND DEVELOPMENT TEAM ? WYETH

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 表达HIV/SIV抗原的重组水泡性口炎病毒(RVSV)的原型载体已被证明能在恒河猴中激发强大的免疫反应，并在与猴-人类免疫缺陷病毒SHIV89.6P攻击后显著降低病毒载量并改变疾病发病机制。然而，当在严格的非人类灵长类动物神经毒力模型中进行测试时，原型rVSV载体似乎不足以用于人类。 在该项目中，7只曾在2005年接种过VSV疫苗的动物于2006年3月27日接受了第二次DNA疫苗接种(第一次接种于2005年10月)。采集粘膜样本和抽血以监测免疫反应，直至2006年5月。 2006年1月，曾在2005年为该项目接种VSV疫苗的19只动物于2006年1月再次接种疫苗。采集血样、体温和粘膜样本，监测免疫反应。其中12只动物于2006年3月从该项目中释放。其余7只动物于2006年6月26日接受了最后一次疫苗接种。样本采集到2006年8月，之后这些动物被从该项目中释放。 进一步的研究计划使用Onlu Mamu Ao1+猴子来确保强烈的免疫反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Prototype recombinant vesicular stomatitis virus (rVSV) vectors expressing HIV/SIV antigens have been shown to elicit robust immune responses in rhesus macaques, and effect a significant reduction in viral load and alter disease pathogenesis following challenge with the simian-human immunodeficiency virus SHIV89.6P. However, when tested in a stringent non-human primate neurovirulence model, the prototype rVSV vector appeared to be inadequately attenuated for use in humans. Seven animals previously vaccinated in 2005 with VSV on this project were given a second DNA vaccine on 3/27/06 (the first was given in Oct. 2005). Mucosal samples and blood draws were collected to monitor immune response through May 2006. In January 2006, nineteen animals previously vaccinated in 2005 with VSV on this project were given another vaccination in January 2006. Blood samples, body temperature and mucosal samples were collected to monitor immune response. Twelve of the animals were released from the project in March 2006. The remaining seven animals received a final vaccination on 6/26/06. Samples were collected through August 2006 after which the animals were released from the project. Additional studies are planned using onlu Mamu Ao1 + monkeys to insure a strong immune response.